­­­Colonoscopy Outcomes in Average-Risk Screening Equivalent Young Adults: Data from the New Hampshire Colonoscopy Registry

Lynn F. Butterly, MD1,2, Rebecca L. Siegel3, MPH3, Stacey Fedewa PhD3, Christina M. Robinson MS1,2, Ahmedin Jemal, DVM3, PhD, Joseph C. Anderson MD1,2,4

1. Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
2. New Hampshire Colonoscopy Registry, Lebanon, NH, United States.

3. Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.

4. White River Junction VAMC, White River Junction VT

**Supplemental Table 1.** Results for co-variates in logistic regression models in Table 2 predicting polyps as stratified across age groups

|  |  |  |  |
| --- | --- | --- | --- |
|  | Any neoplasia OR(95% CI) | Advanced neoplasiaOR(95% CI) | CSSP OR(95% CI) |
| Sex (F versus M) | 0.55(0.52-0.58) | 0.62(0.55-0.69) | 0.90(0.82-0.99) |
| BMI (continuous) | 1.02(1.01-1.02) | 1.02(1.01-1.03) | 1.02(1.01-1.02) |
| Family history (non-first degree relative) | 1.08(0.96-1.23) | 1.14(0.89-1.46) | 1.17(0.95-1.43) |
| Smoking | Never | 1.0(ref) | 1.0(ref) | 1.0(ref) |
| Past | 1.17(1.11-1.24) | 1.27(1.12-1.43) | 1.23(1.11-1.36) |
| Current | 1.82(1.68-1.98) | 1.99(1.71-2.32) | 2.13(1.88-2.43) |
| 5 drinks or more /week | 1.14(1.07-1.21) | 1.08(0.96-1.21) | 1.09(0.99-1.21) |
| Aspirin (1-3 times / week) | 0.84(0.79-0.90) | 0.84(0.74-0.95) | 0.79(0.71-0.88) |
| Education (HS or more) | 0.84(0.72-0.98) | 0.71(0.55-0.93) | 0.83(0.65-1.08) |
| Exercise (once a week or more) | 0.88(0.83-0.92) | 0.83(0.74-0.92) | 0.88(0.80-0.97) |

Advanced neoplasia: Adenomas >1cm, adenomas with villous elements or high-grade dysplasia, or colorectal cancer. Clinically Significant Serrated Polyps: Sessile Serrated Polyps, Traditional Serrated Adenomas, Hyperplastic polyps > 1 cm anywhere in the colon and Hyperplastic polyps > 5 mm and proximal to the rectosigmoid.

Any colorectal neoplasia: Any adenoma or advanced neoplasia

Supplemental Table 2. Outcomes across age groups with non FDR excluded from cohort

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | < 40% (95% CI)(n=2251) | 40-44% (95% CI)(n=1046) | 45-49% (95% CI)(n=1588) | 50-54% (95% CI)(n=20621) | 55-59% (95% CI)(n=6313) | 60+% (95% CI)(n=6856) |
| Advanced Neoplasia | 1.1%(0.7-1.6)(n=24) | 3.1%(2.2-4.3)(n=32) | 3.6%(2.8-4.6)(n=57) | 3.6%(3.3-3.9)(n=740) | 5.1%(4.6-5.7)(n=322) | 6.8%(5.9-7.5)(n=469) |
| CSSP | 2.8%(2.2-3.6)(n=64) | 4.6%(3.5-6.0)(n=48) | 5.8%(4.8-7.1)(n=92) | 6.2%(5.8-6.5)(1271) | 6.7%(6.2-7.4)(n=426) | 5.9%(5.4-6.5)(n=406) |

P < 0.0001 across all groups for all rows

Advanced neoplasia: Adenomas >1cm, adenomas with villous elements or high-grade dysplasia, or colorectal cancer. Clinically Significant Serrated Polyps: Sessile Serrated Polyps, Traditional Serrated Adenomas, Hyperplastic polyps > 1 cm anywhere in the colon and Hyperplastic polyps > 5 mm and proximal to the rectosigmoid.